Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma

Immunotherapy. 2016 Jun;8(6):677-9. doi: 10.2217/imt.16.6.
No abstract available

Keywords: ipilimumab; melanoma; nivolumab; pembrolizumab; survival; toxicity.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • B7-H1 Antigen / immunology
  • CTLA-4 Antigen / immunology
  • Clinical Trials as Topic
  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • Immunotherapy / methods*
  • Ipilimumab / therapeutic use*
  • Melanoma / drug therapy*
  • Melanoma / mortality
  • Nivolumab
  • Programmed Cell Death 1 Receptor / immunology
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • B7-H1 Antigen
  • CTLA-4 Antigen
  • Ipilimumab
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • pembrolizumab